Cartesian Therapeutics, Inc. (RNAC) announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its lead pipeline candidate, Descartes-08, for the treatment of myasthenia gravis (“MG”), an autoimmune disease associated with muscle weakness. Shares of the company were up 3.5% on May 22 following the announcement of the news.The RMAT designation is generally granted by the FDA to therapies that are intended to treat or cure a serious or life-threatening disease and have ...